The UK firm, a nanotechnology partnering focused JV between the University of London School of Pharmacy and Imperial College London, will mange development of an orally-available formulation of a candidate cancer treatment for an undisclosed US biotech developer.
The proof-of-concept project, which will be conducted by researchers at the School of Pharmacy, follows signing of a service level agreement (SLA) with the institution and extends the scope of BNC’s trial support expertise according to CEO David Sarphie.
“The SLA significantly expands our established pool of world class scientist that we manage and draw upon for specific life science projects, including cancer research.”